Surrozen, Inc. (NASDAQ: SRZN) is a Healthcare company (Biotechnology) with a market capitalization of $224M. The Maz Rating grades it against the other companies in its sector.
Surrozen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.98, Surrozen, Inc. trades at 21.5x sales. Over the last twelve months it generated about $10M of revenue and a net loss of $324M. It runs a gross margin of 99.4%, an operating margin of -485.4% and a net margin of -3706.4%. It shows return on equity of 228.0%, return on invested capital of -52.4% and a free cash flow yield of -13.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.56. Over the past 52 weeks the share price ranged from $12.75 to $37.83, with a beta of 0.56.
Surrozen, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Surrozen, Inc. (SRZN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 33.7% / 30% · Interest income / Revenue 91200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 33.7% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 91200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 33.7% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 91200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.30% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 89.7% / 33.33% · Receivables / Avg Assets (4Q) 2.30% / 33.33% · Interest income / Revenue 91200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 92.0% / 33.33% · (Cash+Recv) / Total Assets 92.0% / 33.33% · Interest income / Revenue 91200000.0% / 5% | Fail |
No. As of September 2026, Surrozen, Inc. (SRZN) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Surrozen, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 91200000.0% of each dividend: Surrozen, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.